Mechanisms underlying the QT interval-prolonging - Effects of sevoflurane and its interactions with other QT-prolonging drugs

被引:44
|
作者
Kang, JS [1 ]
Reynolds, WP [1 ]
Chen, XL [1 ]
Ji, JZ [1 ]
Wang, HG [1 ]
Rampe, DE [1 ]
机构
[1] Sanofi Aventis, Dept Drug Safety Evaluat, US Safety Pharmacol, Bridgewater, NJ 08807 USA
关键词
D O I
10.1097/00000542-200605000-00018
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Sevoflurane prolongs ventricular repolarization in patients, but the mechanisms are not fully characterized. The effects of sevoflurane on many cloned human cardiac ion channels have not been studied, and the interactions between sevoflurane and other drugs that prolong cardiac repolarization have not been detailed. Methods: The effects of sevoflurane on action potentials and L-type Ca2+ channels in guinea pig myocytes were examined. Sevofluarane's effects on cloned human cardiac K+ channels and the cloned human cardiac Na+ channel were studied. The consequences of combining sevoflurane and the class III antiarrhythmic drugs sotalol or dofetilide on action potential duration were also examined. Results: Sevoflurane produced an increase in action potential duration at concentrations of 0.3-1 m(M). Contrary to most drugs that delay ventricular repolarization, sevoflurane was without effect on the human ether-a-go-go-related gene cardiac potassium channel but instead produced a reduction in KvLQT1/minK K+ channel currents and inhibited the Kv4.3 K+ channel by speeding its apparent rate of inactivation. Sevoflurane had little effect on Na+ and Ca2+ channel currents at concentrations of 1 mm or less. When the authors coadministered sevoflurane with sotalol or dofetilide, synergistic effects on repolarization were observed, resulting in large increases in action potential duration (up to 66%). Conclusion: Prolonged ventricular repolarization observed with administration of sevoflurane results from inhibition of KvLQT1/minK and Kv4.3 cardiac K+ channels. Combining sevoflurane with class III antiarrhythmic drugs results in supra-additive effects on action potential duration. The results indicate that sevoflurane, when administered with this class of drug, could result in excessive delays in ventricular repolarization. The results suggest the need for further clinical studies.
引用
收藏
页码:1015 / 1022
页数:8
相关论文
共 50 条
  • [1] Effect of QT interval-prolonging drugs taken in pregnancy on the neonatal QT interval
    Michel, Holger
    Potapow, Antonia
    Dechant, Markus-Johann
    Brandstetter, Susanne
    Wellmann, Sven
    Koeninger, Angela
    Melter, Michael
    Apfelbacher, Christian
    Kabesch, Michael
    Gerling, Stephan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Concomitant Prescription of QT-Prolonging Drugs in Dronedarone Users
    Wu, Chuntao
    Koren, Andrew
    Thammakhoune, Jane
    Kechemir, Hayet Kechemir
    Tcherny-Lessenot, Stephanie
    Lin, Stephen
    Juhaeri, Juhaeri
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 81 - 81
  • [5] Predicting Risk of Sudden Death With QT Interval-Prolonging Medications
    Chugh, Nanki
    Bloomfield, Sol
    Leitner, Oliver
    Uy-Evanado, Audrey
    Chugh, Sumeet
    Reinier, Kyndaron
    CIRCULATION, 2020, 142
  • [6] QT for cuties: ECG monitoring in pediatric exploratory ingestion of QT-prolonging drugs
    Burn, June
    Hammack, Jean
    Rasmussen, Marcia
    Smith, Lynette
    Kirschner, Ronald
    CLINICAL TOXICOLOGY, 2017, 55 (07) : 822 - 823
  • [7] Pharmacodynamic Drug–Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients
    Gudrun Hefner
    Martina Hahn
    Christoph Hiemke
    Sermin Toto
    Jan Wolff
    Sibylle C. Roll
    Ansgar Klimke
    Journal of Neural Transmission, 2021, 128 : 243 - 252
  • [8] Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer
    Rowe, Elizabeth J.
    Shugg, Tyler
    Ly, Reynold C.
    Philips, Santosh
    Rosenman, Marc B.
    Callaghan, John T.
    Radovich, Milan
    Overholser, Brian R.
    Schneider, Bryan P.
    Tisdale, James E.
    Skaar, Todd C.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [9] Combinations of QT-prolonging drugs are frequently used in psychiatry.
    Marynissen, T.
    Vandael, E.
    Reyntens, J.
    Foulon, V.
    Willems, R.
    ACTA CARDIOLOGICA, 2013, 68 (05) : 538 - 539
  • [10] Approach to initiating QT-prolonging oncology drugs in the ambulatory setting
    de Lemos, Mario L.
    Kung, Carrie
    Kletas, Victoria
    Badry, Nadine
    Kang, Isabell
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (01) : 198 - 204